Ex-ImClone president John H. Johnson is back in the biotech saddle. Savient Pharmaceuticals named Johnson, who ran Eli Lilly's oncology business after the pharma company snatched up ImClone, as its new CEO. This is Savient's first CEO since late 2008, when Christopher G. Clement abruptly departed. Savient gained an approval for Kystexxa last fall and plan to let Johnson lead its commercialization effort. Story